GlassScriptPhysician profile
William Blake Hubert
NPI 1659704658
$2,532.20
in general payments reported to CMS, 2019-2025
27 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $363 · 2023: $622 · 2024: $673 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.27 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $459.24 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $408.02 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $216.12 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $191.16 | 2024-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $165.08 | 2023-2024 | Inpefa |
| Amgen INC. | $139.81 | 2023-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $133.89 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $128.67 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $124.31 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.83 | 2021-2024 | Jardiance |
| United Therapeutics Corporation | $58.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $52.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $48.35 | 2021-2024 | Wainua |
| Baxter Healthcare | $38.80 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $34.68 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $34.53 | 2022 | |
| Medtronic, INC. | $31.89 | 2023 | Linq II, Tyrx |
| Genzyme Corporation | $30.45 | 2025 | |
| Shockwave Medical, INC | $22.09 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bridgebio Pharma, INC. | $22.02 | 2025 | Attruby |
| Lantheus Medical Imaging, INC. | $20.58 | 2021 | |
| Esperion Therapeutics, INC. | $19.09 | 2023 | Nexletol |
| Irhythm Technologies, INC. | $18.96 | 2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals, LTD. | $16.53 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $14.81 | 2024 | |
| Philips North America LLC | $14.28 | 2022 | |
| Atricure, INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.